Amoxicillin/Metronidazole Dose Impact as an Adjunctive Therapy for Stage II - III Grade C Periodontitis (Aggressive Periodontitis) at 3- And 6-Month Follow-Ups: a Systematic Review and Meta-Analysis

M. Karrabi, Zahra Baghani
{"title":"Amoxicillin/Metronidazole Dose Impact as an Adjunctive Therapy for Stage II - III Grade C Periodontitis (Aggressive Periodontitis) at 3- And 6-Month Follow-Ups: a Systematic Review and Meta-Analysis","authors":"M. Karrabi, Zahra Baghani","doi":"10.5037/jomr.2022.13102","DOIUrl":null,"url":null,"abstract":"ABSTRACT Objectives This systematic review and meta-analysis study sought to review the efficacy of amoxicillin/metronidazole dose and duration time in the treatment of stage II - III grade C periodontitis (aggressive periodontitis) after current follow-up. Material and Methods An electronic search of the literature was performed in three main databases for relevant articles published until 31th of December 2021. According to the PRISMA statement, the extracted data from selected articles were pooled. The weighted mean difference (MD) and 95% confidence interval (CI) of clinical attachment level (CAL) gain and probing depth (PD) reduction at 3 and 6 months of follow-up were calculated. The heterogeneity of the data was evaluated by the I2 test. Results The results of six randomized clinical trials revealed significant improvement of clinical parameters in moderate and severe pockets. Prescription of 400 to 500 mg metronidazole caused significant CAL gain changes just in moderate pockets (MD = 1.82; 95% CI = 1.11 to 2.53; P < 0.05). Conclusions Amoxicillin/metronidazole has positive short-term effects as an adjunct to scaling and root planning for treatment of stage II - III grade C periodontitis. Higher doses of metronidazole (400 to 500 mg) are required for optimal efficacy regarding clinical attachment level gain.","PeriodicalId":230885,"journal":{"name":"Journal of Oral & Maxillofacial Research","volume":"37 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Oral & Maxillofacial Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5037/jomr.2022.13102","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 6

Abstract

ABSTRACT Objectives This systematic review and meta-analysis study sought to review the efficacy of amoxicillin/metronidazole dose and duration time in the treatment of stage II - III grade C periodontitis (aggressive periodontitis) after current follow-up. Material and Methods An electronic search of the literature was performed in three main databases for relevant articles published until 31th of December 2021. According to the PRISMA statement, the extracted data from selected articles were pooled. The weighted mean difference (MD) and 95% confidence interval (CI) of clinical attachment level (CAL) gain and probing depth (PD) reduction at 3 and 6 months of follow-up were calculated. The heterogeneity of the data was evaluated by the I2 test. Results The results of six randomized clinical trials revealed significant improvement of clinical parameters in moderate and severe pockets. Prescription of 400 to 500 mg metronidazole caused significant CAL gain changes just in moderate pockets (MD = 1.82; 95% CI = 1.11 to 2.53; P < 0.05). Conclusions Amoxicillin/metronidazole has positive short-term effects as an adjunct to scaling and root planning for treatment of stage II - III grade C periodontitis. Higher doses of metronidazole (400 to 500 mg) are required for optimal efficacy regarding clinical attachment level gain.
阿莫西林/甲硝唑作为辅助治疗II - III期C级牙周炎(侵袭性牙周炎)3- 6个月随访的剂量影响:一项系统综述和荟萃分析
本系统回顾和荟萃分析研究旨在回顾阿莫西林/甲硝唑剂量和持续时间治疗II - III期C级牙周炎(侵袭性牙周炎)的疗效。材料与方法在三个主要数据库中电子检索截至2021年12月31日发表的相关文献。根据PRISMA声明,将从选定文章中提取的数据汇总。计算随访3个月和6个月时临床附着水平(CAL)增益和探探深度(PD)降低的加权平均差(MD)和95%置信区间(CI)。采用I2检验评估数据的异质性。结果6项随机临床试验结果显示,中重度口袋患者的临床参数均有显著改善。处方400 ~ 500 mg甲硝唑仅在中等口袋中引起显著的CAL增益变化(MD = 1.82;95% CI = 1.11 ~ 2.53;P < 0.05)。结论阿莫西林/甲硝唑治疗II ~ III期C级牙周炎具有良好的短期疗效。需要更高剂量的甲硝唑(400至500毫克)以获得最佳的临床附着水平增益。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信